Priority setting: the case of new drugs. Parallel session: Universal Health Coverage, costing and prioritization
|
|
- Grace Hamilton
- 5 years ago
- Views:
Transcription
1 Priority setting: the case of new drugs Parallel session: Universal Health Coverage, costing and prioritization Dr Jeremy Lauer Health Systems Governance and Financing 1 Department of Health Systems Governance and Financing
2 Priority Setting Asks: What's the best that can be done? (includes all kinds of benefit attributable to the health system see next slide). Is indifferent to what has already been done (so past history is not 'baked in'). Thus, not done at the margin (in economic terms, all constraints relaxed). 2 Department of Health Systems Governance and Financing
3 Priority setting and UHC Universal Health Coverage (UHC): Priority setting within and across the 3 dimensions of the 'UHC cube': 1. Which population groups should be covered first. WHO? 2. Cover more services for the people already covered (and/or increase quality). WHAT (i.e. which services)? 3. Reduce out of pocket payments further for people currently covered with a set of services. HOW MUCH does it cost? Real choices involve a combination of dimensions. 3 Department of Health Systems Governance and Financing
4 UHC cube 4 Department of Health Systems Governance and Financing
5 Decision making Asks "What is the 'next' thing to do?" Or, What do we do now? Depends on what's already been done (past history is be 'baked in'). Done at the margin. 5 Department of Health Systems Governance and Financing
6 Strategic planning Intermediate between Priority setting and Decision-making. Asks, "Given a set of Priorities and a set of Activities, how can we make our activities look more like our priorities?" Looks at time in 'bite-size chunks' (usually 3-10 years). Can be thought of as Decision making that takes account of priorities in forming objectives. Multiple constraints addressed (incl. Affordability). 6 Department of Health Systems Governance and Financing
7 OneHealth Tool for strategic planning Uses results from Priority Setting exercise to set objectives. Allows decision makers (DMs) to quantify: Impact of their national plans on population health Cost of the national plans (Does not currently have a Hepatitis B/C module.) Allows DMs to confirm presence of the necessary: financial resources health workers and health system infrastructure etc. 7 Department of Health Systems Governance and Financing
8 That's the Theory. Now comes the hard part: Practice. 8 Department of Health Systems Governance and Financing
9 New medicines availability Highly effective, highly costly new medicine => 'cost effective' new treatment. Should it be introduced? Depends on: What else it displacing? (not good if it displaces more CE activities => going backwards ) Is it affordable? (will it absorb all available public funding)? Availability of health system platform for delivery and follow up? Etc. 9 Department of Health Systems Governance and Financing
10 Conclusions Keep in mind: Medicines price is a variable, not a constant. Assuming priority etc. has been established, it's useful to ask: At what price will the new therapy become as cost effective as existing alternatives? as cost effective as what is displaced? 10 Department of Health Systems Governance and Financing
11 Health system implications New medicines have important implications for basic health services, which may be weak and under-developed. More cost-effective interventions in such settings include: strengthening early detection and effective treatment. Same implications for many new therapies: Cost effective but not affordable. 11 Department of Health Systems Governance and Financing
12 Cost per year per one million population (I$, log scale) Price analysis: HPV vaccine Cost-effectiveness of cervical cancer interventions Afro-D 10,000,000 I$ 1000/DALY ~current vaccine price CVC-11 CVC-12 1,000, ,000 1-year PAP (I$4220) CVC-2 CVC-6 CVC-13 CVC-14 1-year PAP + treatment (I$1664) (I$ 1 per capita) CVC-7 CVC-16 I$ 100/DALY CVC-3 CVC-15 CVC-10 5-year PAP + treatment (I$637) CVC-9 CVC-19 CVC-18 CVC-22 CVC-1 CVC-24 CVC-8 CVC-30 current scenario (I$ 4179) HPV 35, 40, 45 (I$1445/DALY) CVC-28vaccination + treatment (I$233) CVC-17 CVC-21 CVC-5 VIA, PA 35, 40, 45 (~I$675/DALY) treatment (I$ 209/DALY) CVC-29 I$ 10/DALY CVC-4 vaccination 2 (I$ 288/DALY) VIA 40 (I$ 434/DALY) CVC-27 vaccination 1 (I$ 114/DALY) 10, ,000 10,000 DALYs averted per year per one million population (log scale) 12 Department of Health Systems Governance and Financing
13 The end Thank you! 13 Department of Health Systems Governance and Financing
14 Presenter: Universal Health Coverage (UHC) Costing and Prioritization Regional Plan of Action for the Prevention and Control of Viral Hepatitis in the Americas Massimo N. Ghidinelli Pan American Health Organization/World Health Organization (PAHO/WHO)
15 Viral Hepatitis in the Americas Hepatitis A Hepatitis B Hepatitis C Estimates for the Americas Antibodies to HAV North America: 10% Caribbean: 50% Latin America: 70-90% 7.6 M chronic HBV infection Latin America: 2-4% Amazon Basin: 8% USA, South America : <2% 13 M Caribbean: ~0.7 M (2.1%) North America: ~4.4M(1.3%) Latin America: ~7.6 M (1.2%-2%) 109,000 death/year related to Hepatitis (4) Source: 1. World Health Organization. The global prevalence of hepatitis A. Virus Infection and susceptibility: a systematic review [Internet]. Geneva: WHO; Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol Mar 27;(3): World Health Organization. Guidelines for the screening care and treatment of persons with hepatitis C infection. Geneva: WHO; WHO/ PAHO Mortality Information System (updated in July 2013). 5. Aparna S, Johannes Ho, Rafael T M, Ge rard K, Jo rdis J Ott. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and The Lancet July, 2015
16 % American Member States with routine surveillance for viral hepatitis HAV HBV HVC HDV HEV surveillance of acute hepatitis Source: WHO. Global policy report on the prevention and control of viral hepatitis. Geneva, 2013 PAHO, Situation analysis, Washington DC 2015 (Preliminary data)
17 HepB Vaccine: 3d dose coverage in infants, 2013 Source: Pan American Health Organization. Hepatitis vaccine coverage map, Available at : cine-coverage-map&catid=4217%3afgl03-hepatitis-vaccine-feature&itemid=4329&lang=es
18 Emerging framework for elimination targets by 2030 Focus Indicator Target (reduction from 2010 baseline) Impact Incidence Incidence of Hepatitis B Incidence of Hepatitis C Impact Mortality Deaths due to Hepatitis B Deaths due to Hepatitis C HBV Coverage Infant vaccination Birth dose vaccine Hepatitis B treatment (cascade) 70-90% reduction by % reduction by % + 80% 90, 90, 90 HCV Coverage Risk of medical exposure (in and outside facility) Harm reduction for injecting drug users Hepatitis C treatment (cascade to cure) 75% 50% 90, 90, 90
19 Regional Plan of Action for Viral Hepatitis, Strengthening of strategic information Promotion of an integrated comprehensive response Goal Equitable access to prevention Strengthening lab capacity to support Dx, surveillance & safe blood supply Strengthen regional public health responses to VH Reduction in morbidity and mortality related to VH Fostering equitable access to clinical care
20 PAHO s Plan of Action for Prevention and Control of Viral Hepatitis Promoting an integrated comprehensive response Indicator Baseline Target Number of countries that have a structured and budgeted national strategy or plan related to prevention, treatment, and control of viral hepatitis 10 in 2015 a Number of countries with goals of elimination of hepatitis B and Hepatitis C as public health problems 0 in 2015 a Number of countries with goals of elimination of mother-to-child transmission of hepatitis B Number of countries that commemorate World Hepatitis Day through awareness campaigns or major thematic events 1 in 2012 b 5 10 in 2015 a 20
21 PAHO s Plan of Action for Prevention and Control of Viral Hepatitis Fostering equitable access to preventive care Indicator Baseline Target Number of countries that maintain high HBV coverage (95% or above) as part of the routine childhood vaccination schedule (below 1 year of age) 15 in 2013 c Number of countries that have included immunization of newborns against HBV within the first 24 hours in their vaccination programs Number of countries that have conducted HAV epidemiological, burden of disease, and health technology assessment, such as cost-effectiveness analyses to inform vaccine introduction 18 in 2013 c 25 5 in 2013 d Number of countries with measures for the prevention of hepatitis B among health workers 13 in 2015 a Number of countries with viral hepatitis prevention and control strategies, such as HBV vaccine targeting key populations 8 in 2015 a 20
22 PAHO s Plan of Action for Prevention and Control of Viral Hepatitis Fostering equitable access to clinical care Indicator Number of countries that have developed guidelines for prevention, care, and treatment of hepatitis B in line with latest WHO recommendations Number of countries that have developed guidelines for screening, diagnosis, care, and treatment of hepatitis C in line with latest WHO recommendations Baseline Target 16 in 2012 b 25 6 in 2015 a Number of countries that have started offering publicly funded HBV diagnosis and treatment 11 in 2015 a Number of countries that have started offering publicly funded HCV diagnosis and treatment 6 in 2015 a Number of countries that include in their national essential medicine lists and/or formularies one or more drugs recommended in WHO 2015 guidelines for HBV treatment Number of countries that include in their national essential medicine lists and/or formularies one or more drugs recommended in WHO 2014 guidelines for HCV treatment Number of countries that have updated their antiretroviral treatment criteria, including the recommendation of initiating antiretroviral therapy (ART) regardless of CD4 count in HIV patients with severe HBV-related chronic liver disease 10 in 2015 a 15 8 in 2015 a in 2014 e 30
23 PAHO s Plan of Action for Prevention and Control of Viral Hepatitis Strengthening strategic information Indicator Baseline Target Number of countries that report cases of acute and chronic hepatitis B Number of countries that report cases of hepatitis C infection Number of countries conducting surveys on prevalence of viral hepatitis B or C in general population and/or key populations Number of countries that have published a national report on viral hepatitis 8 in 2015 a in 2015 a in 2015 a 18 8 in 2015 a 15
24 PAHO s Plan of Action for Prevention and Control of Viral Hepatitis Strengthening laboratory capacity to support diagnosis, surveillance, and a safe blood supply Indicator Baseline Target Number of countries that implement standardized and effective technologies for HBV patient monitoring, 10 in 2015 a Number of countries that implement standardized and effective technologies for HCV confirmation, genotyping, and patient monitoring 8 in 2015 a Number of countries that screen 100% of blood transfusion units for HBV and HCV 39 in 2014 f 41
25 Regional Framework for Surveillance and Monitoring of HBV and HCV Case reporting Case based surveillance with unique identifiers Serologic surveillance Surveillance of outcomes Monitoring of response Population-based studies Sub-population studies: pregnant women, MSM, SW, IDU, indigenous, blood banks Chronic liver disease surveillance Hepatic carcinoma incidence Liver transplant surveillance Mortality due to hepatic carcinoma, cirrhosis, liver failure Immunization HBV Testing coverage Linkage and retention in care Treatment Sustained virological response Care & Treatment cascade for people with chronic HCV infection Chronic HCV infection Diagnosis+ confirmation (HCV-RNA) Linked to care (staging) Eligible for treatment Treatment for HCV Sustained virological response
26 Cost of HCV associated diseases, , , ,000 Hep Encephalopathy HCC Liver TX 55,000 5,000 Americas Asia Pacific Europe USA Source: A. C. El Khoury, W. K. Klimack, C. Wallace, H. Razavi. Economic burden of hepatitis C-associated diseases in the United States. Journal of Viral Hepatitis, 2012, 19, A. C. El Khoury, W. K. Klimack, C. Wallace, H. Razavi: Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics Vol. 15, No. 5, 2012,
27 Hepatitis C Treatment costs (12 weeks) 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10, weeks Source: University of Washington. Hepatitis C online,
28 Total estimated cost to fully vaccinate a child against Hepatitis B in the Americas Vaccine Schedule (birth dose) Doses/ child Cost/ dose Wastage Total cost Hepatitis B* 1+0 (infant dose) 1 $ $ 0.27 DPT-Hepatitis B-Hib (Pentavalent)* 3+0 (2, 4 and 6 mo) 3 $ $ 7.15 VACCINE ONLY $ 7.42 with CIF, syringe and safety box** 4 $ 3.28 $ with all other delivery costs** 4 $ 6.20 $ OTHER ONLY $ TOTAL COST PER CHILD (Vaccine, supply, delivery, other) $ * Vaccine price/dose represents PAHO RF prices for 2015 ** CIF, syringe, safety box and delivery costs data based on facility-based costing exercise in Honduras (Janusz et al. 2015)
29 Hepatitis B Cost estimates (30 days) Medicine Generic* R&D * Entecavir $ $ $ ,00 Tenofovir $ $99.00 $ *Canada Source:
30 Acknowledgments Laura Alves PAHO/VH Mónica Alonso PAHO/VH Alba Maria Ropero PAHO/IM Cara Janusz PAHO/IM Homie Razavi CDA
31 Universal health coverage, costing and priorization Presenter: Marcelo C. Moscoso Naveira, MD MPH General Coordinator of Viral Hepatitis Ministry of Health of Brazil
32 Brazil & The Unified Health System 1988 Constitution: Unified Health System (SUS) Health: a citizen s right and an obligation of the state Universal access to health services Equality of access to health care Integrality and continuity of care Decentralization Social Participation
33 The Process Multiple levels of care Improvements + Sustainability Priorities defined by epidemiological data Hepatitis B: 1989 Hepatitis C: 2002 Constant monitoring and evaluation
34 Steps Social Mobilization Right to Vote Hep B Vaccine Harm Reduction Family Health Strategy Blood Safety PEG-IFN, 3TC, TDF National Program for Viral Hepatitis Mais Médicos Rapid Tests Entecavir Boceprevir/Telaprevir Daclatasvir Simeprevir Sofosbuvir
35 Epidemiology & UHC Hepatitis B cases, Brazil Hepatitis C cases, Brazil
36 Trends & UHC VH hospitalizations and deaths, Brazil HCC hospitalizations and deaths, Brazil ,000 10,000 9,000 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1, ,000 9,000 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,
37 Costs & UHC Rapid Testing: 5 USD Over 5 million tests distributed in 2014 Hepatitis B treatment (TDF/ETV): USD/mo Approximately 50,000 treatments/year Hepatitis C treatment (DAAs): 9,425 9,625 USD Accumulated over 100,000 treatments since 2002 Over 15,000 treatments in 2014
38 Costs & UHC Liver Transplant: 54,698 75,434 USD Over 1,700 transplants/year 8,000 new HCC/cases/year Family Health Strategy: R$ 5,00/per capita/mo less than 1 Approximately 50 million people
39 Big Picture Liver failure and transplant Comorbidities Indications for treatment Access to treatment and fibrosis assessment Diagnosis Awareness Careful evaluation of new technologies Several actors, administrative responsibility Commitment
40 HCV Perspectives Sustained Virological Response (SVR) >90% 40% INTERFERON- FREE SOF+DAC/SIM (2015-) PR/PR+BOC/TEL ( ) F3/F4 (F2)* Treatments/year F3/F4 (F2), HIV, Pr/P Tx... Population
41 Obrigado
54th DIRECTING COUNCIL
54th DIRECTING COUNCIL 67th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS Washington, D.C., USA, 28 September-2 October 2015 Agenda Item 4.10 CD54/13, Rev. 1 2 October 2015 Original: English
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationGlobal strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators
Global strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators Antons Mozalevskis WHO Regional Office for Europe EMCDDA DRID National Expert Meeting Lisbon, 6
More informationSTRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF
PROGRAMME NATIONAL DE LUTTE CONTRE LES HEPATITES STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL (2019-2023) POLICY BRIEF 1 INVESTING IN THE FIGHT AGAINST HEPATITIS B AND C IN SENEGAL NATIONAL STRATEGIC
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
8 April 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH PROGRAMME SUBCOMMITTEE Sixty-fourth session Brazzaville, Republic of Congo, 9 11 June 2014 Provisional agenda item 6 VIRAL HEPATITIS: SITUATION
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
5 November 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-fourth session Cotonou, Republic of Benin, 3 7 November 2014 Provisional agenda item 11 VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES
More informationOvercoming barriers to access to hepatitis C treatment in a rapidly changing landscape
Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment
More informationNeed for Chronic Viral Hepatitis Monitoring System
Need for Chronic Viral Hepatitis Monitoring System Harry L.A. Janssen Dept. of Gastroenterology & Hepatology Erasmus University Medical Center Rotterdam The Netherlands Rotterdam November 2008 National
More informationPLAN OF ACTION FOR THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
PLAN OF ACTION FOR THE PREVENTION AND CONTROL OF VIRAL HEPATITIS Plan of Action for the prevention and control of Viral Hepatitis Washington, D.C. 2016 54th DIRECTING COUNCIL 67th SESSION OF THE REGIONAL
More informationViral Hepatitis Burden and Policy Directions in the European Region of WHO
Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all
More informationChallenges for viral hepatitis prevention in Latin American
Challenges for viral hepatitis prevention in Latin American One in three people on earth has been exposed to hepatitis B or C viruses (HBV and HCV); HBV and HCV are responsible for 57% of cirrhosis and
More informationHepatitis and HIV Co-Infection: Situation in Ukraine.
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV Hepatitis and HIV Co-Infection: Situation in Ukraine. Pavlo Skala Associate Director: Policy & Partnership Ukraine
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item 12.3 28 March 2014 Hepatitis Improving the health of patients with viral hepatitis Report by the Secretariat 1. The Executive Board at
More informationHepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
More informationGlobal reporting system for hepatitis (GRSH) project description
Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationTANZANIA NATIONAL STRATEGIC PLAN FOR CONTROL OF VIRAL HEPATITIS
TANZANIA NATIONAL STRATEGIC PLAN FOR CONTROL OF VIRAL HEPATITIS 2017-2021 A Draft ANGELINA C. SIJAONA THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDREN
More informationPrevention and control of hepatitis B and C in the European Region of WHO
Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationEconomic and societal impact of direct-acting antiviral therapy in Hepatitis C Zoltán Kaló
Economic and societal impact of directacting antiviral therapy in Hepatitis C Zoltán Kaló Professor of Health Economics ISPOR 19th Annual European Congress November 2 nd 2016 ATHCV16099925102016 Concerns
More informationSixty-sixth session Addis Ababa, Federal Democratic Republic of Ethiopia, August 2016
21 August 2016 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-sixth session Addis Ababa, Federal Democratic Republic of Ethiopia, 19 23 August 2016 Agenda item 14 PREVENTION, CARE AND TREATMENT
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationHEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?
HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? Ganiyat Kikelomo OYELEKE FMCP Hepatologist & Gastroenterologist Lagos University Teaching Hospital, Nigeria. INTEREST 2018, KIGALI CONFERENCE
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationHepatitis B mother to child transmission
Hepatitis B mother to child transmission Key issues from Asia and Latin America Nick Walsh Pan American Health Organization/ WHO Regional Office for the Americas Acknowledgements PAHO Massimo Ghidinelli
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationImproving efficiency in health. Hepatitis C virus session
Improving efficiency in health Hepatitis C virus session Aims of this session Optima is a tool to assist in reducing the burden of diseases by optimizing resource allocation. This session will discuss:
More informationAction plan for the health sector response to viral hepatitis in the WHO European Region
Action plan for the health sector response to viral hepatitis in the WHO European Region Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Albania Country Meeting: Tirana, 27-28 October 2016 Chronic
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationHow has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH
How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationIntegrating Hepatitis C into Drug Treatment Settings
Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis
More informationIdentification and management of chronic viral hepatitis in Russia
Technical Viral Hepatitis Prevention Board Meeting IDENTIFICATION AND MANAGEMENT OF PERSONS WITH CHRONIC VIRAL HEPATITIS IN EUROPE Budapest, Hungary, March 18-19, 21 Identification and management of chronic
More informationHepatitis situation in the Republic of Macedonia
Hepatitis situation in the Republic of Macedonia Presented by Viktorija Chaloska Ivanova University Clinic of Gastroenterology Skopje, Republic of Macedonia Hepatitis Prevalence/incidence in Macedonia
More informationGlobal Epidemiology and Prevention of Hepatitis B
Global Epidemiology and Prevention of Hepatitis B Dr. Steven Wiersma WHO Geneva Strengthening immunisation systems and introduction of hepatitis B vaccine in Central and Eastern Europe and the Newly Independent
More informationTitle of the presentation
. Title of the presentation Economic analyses for hepatitis elimination Subtitle of the presentation, lorem ipsum dolor sit amet. Yvan Hutin, Global Hepatitis Programme, World Health Organization November
More informationViral Hepatitis: A Global Snapshot of Challenges and Opportunities
Viral Hepatitis: A Global Snapshot of Challenges and Opportunities John W. Ward, MD, Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention Division of Viral Hepatitis National Center
More informationGlobal, regional and national strategic planning for viral hepatitis prevention and control
Global, regional and national strategic planning for viral hepatitis prevention and control Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Baltic Meeting 19 20 November 2015 Riga, Latvia Presentation
More informationCall to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China
Call to Action Global and Regional Hepatitis Action Plans: Opportunities and considerations for China Po-Lin Chan, Senior Advisor Hepatitis/HIV/STI Lan Zhang, Senior Medical Officer Hepatitis/HIV/STI WHO
More informationFINANCIAL DISCLOSURE
FINANCIAL DISCLOSURE People who work at NIH only dream about having financial disclosures Wait, this just in. The US government has now banned dreaming CRITICAL NON-FINANCIAL DISCLOSURES Nothing I say
More informationTechnical matters: Viral hepatitis
REGIONAL COMMITTEE Provisional Agenda item 8.6 Sixty-seventh Session SEA/RC67/29 Dhaka, Bangladesh 9 12 September 2014 28 July 2014 Technical matters: Viral hepatitis Viral hepatitis is a serious public
More informationTreatment and Access to Drugs
Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,
More informationGlobal health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )
Regional Committee for Europe 65th session EUR/RC65/Inf.Doc./3 Vilnius, Lithuania, 14 17 September 2015 2 September 2015 150680 Provisional agenda item 3 ORIGINAL: ENGLISH Global health sector strategies
More informationResolution. REGIONAL COMMITTEE FOR THE EASTERN MEDITERRANEAN October 2009
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE Resolution REGIONAL COMMITTEE FOR THE EM/RC56/R.5 EASTERN MEDITERRANEAN October 2009 Fifty-sixth Session Agenda item 6 (a) The growing threats
More informationSandi Mitchell Nurse Educator Clinical Prevention Services BCCDC
Sandi Mitchell Nurse Educator Clinical Prevention Services BCCDC sandi.mitchell@bccdc.ca Hepatitis A, B and C Testing Transmission Treatment What Is Hepatitis? Hepatitis means inflammation of the liver
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD
ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD 17 May 2018 Bucharest, Romania Organisers Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe
More informationHomie Razavi. CDA Foundation Polaris Observatory. From Economic Analysis to Financial Dialogue
Homie Razavi CDA Foundation Polaris Observatory From Economic Analysis to Financial Dialogue The CDA Foundation Accelerate hepatitis B and C elimination through verified data, modeling, intervention strategies,
More informationIntegration of collaborative TB/HIV activities with harm reduction services
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases control, Head of Department on HIV/AIDS combating
More informationLatest Funding Trends in AIDS Response
Latest Funding Trends in AIDS Response 20 th International AIDS Conference Melbourne, Australia J.V.R. Prasada Rao United Nations Secretary-General s Special Envoy for AIDS in Asia and the Pacific 21 July
More informationViral Hepatitis Prevention Board
Viral Hepatitis Prevention Board Prevention and control of viral hepatitis in Albania and neighbouring countries: lessons learnt and the way forward TIRANA, ALBANIA 27-28 October 2016 Objectives To provide
More informationCivil Society Driven Response in Ukraine: A program making a difference and bringing results
Civil Society Driven Response in Ukraine: A program making a difference and bringing results CATIE Forum Making it work: From Planning to Practice October 16th, 2015 Andriy Klepikov International HIV/AIDS
More informationHEPATITIS C ELIMINATION IN GREECE
HEPATITIS C ELIMINATION IN GREECE ANGELOS HATZAKIS Professor of Epidemiology & Preventive Medicine Athens University Medical School Co-Chair, Hepatitis B & C Public Policy Association London, UK June 5,
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationCost-effectiveness, Affordability, and Financing of Cervical Cancer Prevention
Cost-effectiveness, Affordability, and Financing of Cervical Cancer Prevention Dr. Carol Levin PATH Video transcript is located below each slide. Cost-effectiveness, Affordability, and Financing of Cervical
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationAction plan for the health sector response to viral hepatitis in the WHO European Region
REGIONAL COMMITTEE FOR EUROPE 66th SESSION Copenhagen, Denmark, 12 15 September 2016 Action plan for the health sector response to viral hepatitis in the WHO European Region istock/todor Tsvetkov Working
More informationPrevention of Hepatitis in risk groups and hepatitis and HIV in Albania. Ass.Prof. Najada COMO
VHPB Meeting Prevention of Hepatitis in risk groups and hepatitis and HIV in Albania Ass.Prof. Najada COMO Infectious Diseases Clinic UHC Mother Theresa Tirane Rogner, Tirane, Albania, 27 28 October 2016
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationCHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND
CHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND Brian J McMahon MD Clinical and Medical Director Liver Disease & Hepatitis Program ANTHC and Research Associate, CDC Alaska
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationWPR/RC68/7 page 7 ANNEX
page 7 ANNEX DRAFT Regional Framework for the Triple Elimination of Mother-to-child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018 2030 page 8 page 9 Table of Contents Abbreviations....
More informationELIMINATING VIRAL HEPATITIS
ELIMINATING VIRAL HEPATITIS THE INVESTMENT CASE Report of the WISH Viral Hepatitis Forum 2018 Alisa Pedrana Jess Howell Sophia Schröder Nick Scott David Wilson Christian Kuschel Lisa Aufegger Margaret
More informationAccess to HCV treatment in Egypt
Access to HCV treatment in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution
More informationToronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally A call for coordinated action Disclaimer Toronto declaration is not aiming to reinvent the wheel or interfere
More informationChildren and AIDS Fourth Stocktaking Report 2009
Children and AIDS Fourth Stocktaking Report 2009 The The Fourth Fourth Stocktaking Stocktaking Report, Report, produced produced by by UNICEF, UNICEF, in in partnership partnership with with UNAIDS, UNAIDS,
More informationCancer prevention and control in the context of an integrated approach
SEVENTIETH WORLD HEALTH ASSEMBLY A70/32 Provisional agenda item 15.6 13 April 2017 Cancer prevention and control in the context of an integrated approach Report by the Secretariat 1. In January 2017, the
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationRegional Action Plan for Viral Hepatitis in the Western Pacific
WORLD HEALTH ORGANIZATION REGIONAL OFFICE OF THE WESTERN PACIFIC Regional Action Plan for Viral Hepatitis in the Western Pacific Draft for virtual consultation A regional priority action plan for awareness,
More informationUnderstanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
More informationA national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD
A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia Prof. Mojca Matičič, MD, PhD Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationAn Electronic Web-based HCV Quality of Care Performance Measurement Program for NYC and NYS. Jeremy Fagan, PhD March QAC Meeting 3/10/2016
An Electronic Web-based HCV Quality of Care Performance Measurement Program for NYC and NYS Jeremy Fagan, PhD March QAC Meeting 3/10/2016 HCV Treatment TimeLine 1 st GEN PIs Boceprevir Telaprevir All-Oral,
More informationViral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician
Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Outline: Virology HBV + pregnancy HCV + new treatments Cases Hepatitis Foundation HBV: virus HBsAg far in excess of complete virions,
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationNational Hepatitis plan. Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology
National Hepatitis plan Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology National hepatitis Plan Hepatitis B: plan non existent. People s migration from endemic countries. Reimbursement
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More informationS P. Optimizing HIV/AIDS prevention programs: towards multidimensional allocative efficiency. Sergio Bautista Paola Gadsden Stefano M Bertozzi
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P Optimizing HIV/AIDS prevention programs: towards multidimensional allocative efficiency Sergio Bautista
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationThe birthof the Dutch National hepatitis plan
Improving Mental Health by Sharing Knowledge The birthof the Dutch National hepatitis plan A success story in many parts Esther Croes MD PhD WHO: framework for global action In 2012 the WHO stated: viral
More informationThe National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015
The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 December 21, 2015 2 December 21, 2015 3 Can we eliminate hepatitis C? Treatments December 21, 2015 4 We Have the Roadmap
More informationIntroduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa
Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa Nigeria Center for Disease Control Federal Ministry of Health Abuja July 2015 Outline 1. Measles disease 2. Progress towards
More informationVHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS
POST-IT @ VHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS East challenges Risk group vaccination problems Problems of anti-vaccine lobby Importance of
More information